Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).

Nagla Fawzy Abdel Karim(Augusta University), Abdul Rafeh Naqash(Oklahoma City University), Hirva Mamdani(Wayne State University), David C. Portnoy(Campbell Clinic), Rebecca Feldman(Caris Life Sciences (United States)), Ihab Eldessouki(Augusta University), Alexander I. Spira(Virginia Cancer Specialists), C. Patrick(Penn State Milton S. Hershey Medical Center), Chisom Onuoha(Augusta University), Stephen V. Liu(Georgetown University), Imran Ahmad(Howard Hughes Medical Institute)
Journal of Clinical Oncology
May 20, 2019
10.1200/jco.2019.37.15_suppl.e14272
Cited by 2

Related Papers

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
|The Lancet Oncology|2015|954
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818